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There are a vast number of neurodegenerative diseases, including Alzheimer’s disease
(AD), Parkinson’s disease (PD), and Huntington’s disease (HD), associated with the
rearrangement of specific proteins to non-native conformations that promotes aggregation
and deposition within tissues and/or cellular compartments.These diseases are commonly
classified as protein-misfolding or amyloid diseases.The interaction of these proteins with
liquid/surface interfaces is a fundamental phenomenon with potential implications for
protein-misfolding diseases. Kinetic and thermodynamic studies indicate that significant
conformational changes can be induced in proteins encountering surfaces, which can play
a critical role in nucleating aggregate formation or stabilizing specific aggregation states.
Surfaces of particular interest in neurodegenerative diseases are cellular and subcellular
membranes that are predominately comprised of lipid components. The two-dimensional
liquid environments provided by lipid bilayers can profoundly alter protein structure and
dynamics by both specific and non-specific interactions. Importantly for misfolding dis-
eases, these bilayer properties can not only modulate protein conformation, but also exert
influence on aggregation state. A detailed understanding of the influence of (sub)cellular
surfaces in driving protein aggregation and/or stabilizing specific aggregate forms could
provide new insights into toxic mechanisms associated with these diseases. Here, we
review the influence of surfaces in driving and stabilizing protein aggregation with a specific
emphasis on lipid membranes.
Keywords: amyloid disease, lipid membranes, protein aggregation, Alzheimer’s disease, Huntington’s disease,
Parkinson’s disease, prion disease
INTRODUCTION
A common motif of several neurodegenerative diseases is the
ordered aggregation of specific proteins, leading to their depo-
sition in tissues or cellular compartments (Chiti and Dobson,
2006). Often referred to as protein conformational or misfold-
ing disorders, such diseases include Alzheimer’s disease (AD),
Parkinson’s disease (PD), Huntington’s disease (HD), amyloidoses,
α1-antitrypsin deficiency, and the prion encephalopathies to name
a few. The common structural motif of protein aggregates asso-
ciated with these diseases is the formation of extended, β-sheet
rich fibrils, referred to as amyloid. Despite no apparent correla-
tion between aggregating proteins in size or primary amino acid
sequence, the characteristic lesions of each disease typically con-
tain fibrillar structures with common biochemical characteristics
(Dobson, 2003; Chiti and Dobson, 2006), indicating the potential
for a conserved mechanism of pathogenesis linking these phe-
notypically diverse diseases. The earliest potential event in the
disease process may be the conversion of a protein to a criti-
cal abnormal conformation, resulting in toxic gain of function
for the monomer, and/or the formation of toxic nanoscale aggre-
gates (Figure 1; Naeem and Fazili, 2011). The elusive toxic species,
whether monomeric or higher-order, may subsequently initiate a
cascade of pathogenic protein–protein interactions that culminate
in neuronal dysfunction. The precise timing of such interactions
and the mechanisms by which altered protein conformations or
aggregates trigger neuronal dysfunction are unclear.
The formation of fibrils often proceeds via a heterogeneous
mixture of intermediate aggregate structures, including a variety of
protofibrils and oligomers (Figure 1). Amyloid formation typically
occurs via a nucleation-growth mechanisms that features an ini-
tial lag-phase due to a thermodynamically unfavorable nucleation
event (Lomakin et al., 1996; Murphy, 2002; Chiti and Dobson,
2006). Once nucleation occurs, aggregation proceeds via an expo-
nential growth phase associated with the addition of monomers
into aggregate forms. The initial lag-phase can be circumvented
by the presence of pre-existing aggregates that can act as seeds for
amyloid formation (Lansbury, 1997; Hu et al., 2009; Langer et al.,
2011; Hamaguchi et al., 2012). To further complicate the issue,
several aggregates have been identified that may be off-pathway to
fibril formation, such as annular structures (Wetzel, 1994; Wacker
et al., 2004). While there are often specific mutations or dysfunc-
tional processing that can be directly linked to aggregation, the
www.frontiersin.org March 2013 | Volume 4 | Article 17 | 1
Burke et al. Surfaces influence amyloid formation
FIGURE 1 | A generic aggregation scheme for amyloid-forming
proteins. Proteins fold into their native structure, which is typically a low
free energy configuration. However, the energy landscape for protein
folding often can have localized minima in which a protein can become
trapped into a misfolded conformation, which can lead to aggregation into
β-sheet rich amyloid fibrils. The formation of fibrils often proceeds through
a heterogeneous mixture of intermediate species, including oligmers and
protofibrils. Off-pathway aggregates can also form, such as annular
aggregates. These aggregates accumulate into amyloid plaques or
inclusions in the diseased brain. The aggregation pathway for any given
amyloid-forming protein can vary considerably depending on the protein
and its folding environment.
nature, and location of protein aggregates in vivo depends on
the specific protein associated with disease. The specific protein
involved also influences the specific form of the critical aggregation
nucleus. For example, synthetic polyglutamine (polyQ) peptides
are thought to have a monomeric critical nucleus (Chen et al.,
2002a,b; Wetzel, 2012); however the addition of flanking sequences
associated with the first exon of the huntingtin (htt) protein can
change the size of the critical nucleus to a tetramer (Jayaraman
et al., 2012; Wetzel, 2012). This can be further modulated by the
addition of β-hairpin motifs within the polyQ domain (Kar et al.,
2013). The extent of the lag-phase, and subsequent aggregation
of polyQ peptides and htt proteins is dependent on the size of
the polyQ domain (Legleiter et al., 2010; Kar et al., 2011). As pro-
tein aggregation often progresses from misfolded monomers to
oligomeric precursors and finally mature fibrils, intensive research
activity has been devoted to determining the most toxically rele-
vant aggregate species in many of these diseases. This is particularly
important, as for the vast majority of these diseases, there are no
widely effective preventative measures or therapeutic treatments.
Fibril structures associated with several different amyloid-
forming proteins have been experimentally resolved, and a com-
mon motif of fibrillar aggregates is a cross-β structure (Eanes
and Glenner, 1968; Glenner et al., 1971; Kirschner et al., 1986;
Sunde et al., 1997; Berriman et al., 2003; Tycko and Ishii, 2003;
Tycko, 2004, 2006; Nelson et al., 2005; Fandrich, 2007). While
the structural spine of fibrils share this common intermolecular
β-sheet structure, a variety of possibilities are available for the
packing of protofilaments into the fibril structure, even for the
same protein/peptide. This variability can lead to distinct amyloid
fibril morphologies. Such variable protofilament arrangements
give rise to distinct fibril morphologies, often termed polymor-
phisms (Kodali and Wetzel, 2007). For example, Aβ has been
shown to form a variety of fibril structures in vitro dependent
on the peptide preparation and aggregation conditions (Kodali
et al., 2010). Furthermore, fibril polymorphs have been observed
for several other amyloid-forming proteins, such as calcitonin
(Bauer et al., 1995), amylin (Goldsbury et al., 1997), glucagon
(Pedersen et al., 2006), the SH3 domain of phosphatidylinositol-
3′-kinase (Jimenez et al., 1999; Chamberlain et al., 2000; Pedersen
et al., 2006), insulin (Bouchard et al., 2000; Jimenez et al., 2002;
Dzwolak et al., 2004), and lysozyme (Chamberlain et al., 2000).
Polymorphic fibrils can differ in the cross-sectional thickness or
helical pitch of the fibril, which can be observed via high resolution
imaging techniques like transmission electron microscopy (TEM)
and atomic force microscopy (AFM) or distinguished with spec-
troscopic techniques like circular dichroism (CD; Petkova et al.,
2005; Kurouski et al., 2010, 2012; Mossuto et al., 2010; Norlin
et al., 2012). While polymorphs are often observed for various
in vitro aggregation reactions, polymorphs have been observed
in amyloid fibrils extracted from tissue as well (Crowther and
Goedert, 2000; Jimenez et al., 2001), affirming that in vivo aggre-
gation can be heterogeneous and complex. Furthermore, it has
been proposed that polymorphic fibrils may result in distinct
biological activities and variable toxicity related to the different
aggregate structures (Seilheimer et al., 1997; Petkova et al., 2005).
These distinct fibril morphologies may also have distinct aggre-
gate intermediates associated with their formation, adding to the
heterogeneity of potential protein aggregates and further com-
plicating efforts aimed at elucidating the relative role of discrete
aggregates in disease-related toxicity.
While protein preparation and environment influence the
structural polymorphs of protein aggregates in vitro, determining
what environmental factors influence aggregation in vivo remains
difficult. However, the interaction of proteins at solid interfaces,
including cellular membranes comprised of lipid bilayers, may
prove to be a fundamental phenomenon with potential implica-
tions for protein-misfolding diseases. Solid surfaces, such as mica,
graphite, gold, and Teflon, have been shown to heavily influence
aggregation kinetics and the resulting aggregate morphology for
a variety of amyloid-forming proteins (Goldsbury et al., 1999;
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Hoyer et al., 2004; Morriss-Andrews and Shea, 2012). A variety
of kinetic and thermodynamic studies point to significant confor-
mational changes being induced in proteins encountering surfaces
(Gray, 2004). These surface induced conformational changes in
proteins could play a critical role in nucleating amyloid formation
or altering aggregate morphology to specific toxic species. Such
phenomenon are well demonstrated by a study of immunoglob-
ulin light-chain aggregation on mica (Zhu et al., 2002). Small
pieces of mica were incubated in solutions containing a recombi-
nant amyloidogenic light-chain variable domain of smooth muscle
actin (SMA) antibody, under conditions in which fibrils normally
do not form (i.e., low concentration and no agitation). At short
times, amorphous aggregates appeared on mica, and fibrils were
observed within 10 h and fibrils were not formed in the solution
within the same time frame. The fibrils on the surface of mica grew
from the amorphous aggregates and the assemblies of oligomers
present on mica. The use of such solid surfaces as model sys-
tems provides the opportunity to elucidate how specific surface
environment influence protein aggregation.
In regards to disease-related protein aggregation, surfaces of
more physiological relevance are cellular and subcellular mem-
branes that are predominately comprised of lipid bilayers. Like
solid surfaces, the presence of lipid membranes can alter the
aggregation of disease-related proteins by increasing aggregation
rates, nucleating aggregation, promoting specific polymorphs, or
even stabilizing potentially toxic, transient aggregate intermedi-
ates. A significant question remains regarding why amyloid fibrils
form in vivo at concentrations that are orders of magnitude lower
(Seubert et al., 1992) than the critical nucleation concentrations
required in vitro (Lomakin et al., 1996; Sabate and Estelrich, 2005).
A possible answer is the ability to create local concentrations of
protein adsorbed onto molecular surfaces, such as cellular and
subcellular membranes (Kim et al., 2006; Aisenbrey et al., 2008).
Lipid interaction appears to be a common modulator in fibril
formation, as studies of α-synuclein (α-syn; Jo et al., 2000, 2004;
Necula et al., 2003), islet amyloid polypeptide (IAPP; Knight and
Miranker, 2004), and β-amyloid (Aβ; McLaurin and Chakrabartty,
1996, 1997; Choo-Smith et al., 1997; Yip and McLaurin, 2001;
Yip et al., 2002) all demonstrate accelerated fibril formation in a
membrane environment in comparison to bulk solution. General
physicochemical properties of lipid membrane, including phase
state, bilayer curvature, elasticity, and modulus, surface charge,
and degree of hydration, modulate protein aggregation (Gorbenko
and Kinnunen, 2006). The exact chemical composition and lipid
constituents of a lipid bilayer can also influence the aggregation
process (Evangelisti et al., 2012). Potentially important chemical
properties of membrane components include the extent of acyl
chain unsaturation, conformation and dynamics of lipid head-
groups and acyl chains, and protein–lipid selectivity arising from
factors such as the hydrophobic matching at the protein–lipid
interface (Jensen and Mouritsen, 2004). Although lipid bilayers
may act catalytically to induce aggregation by providing envi-
ronments that promote protein conformation and orientation
conducive to fibril assembly (Thirumalai et al., 2003; Sparr et al.,
2004; Zhao et al., 2004), cell membranes may also be targeted by
protein aggregates to induce physical changes in the membrane,
leading to dysfunction and cell death. This may be due to the
ability of amyloid-forming peptides to induce membrane perme-
abilization by altering bilayer structure via the sequestration of
membrane components into fibrils (Michikawa et al., 2001; Lins
et al., 2002; Sparr et al., 2004; Zhao et al., 2004; Valincius et al.,
2008) or by forming unregulated pore-like structures (Jang et al.,
2007). A variety of amyloid-forming proteins, including Aβ, IAPP,
and htt, have been show to locally change the rigidity of model lipid
bilayers in a generic manner (Burke et al., 2013). Furthermore, the
presence of lipid membranes can also influence the ability of small
molecules to prevent or destabilize protein aggregates, having a
major impact on several therapeutic strategies. Such a scenario has
been demonstrated experimentally as (-)-epigallocatechin gallate
(EGCG), which has been shown to inhibit the aggregation of sev-
eral amyloid-forming proteins in the absence of surfaces (Bieschke
et al., 2010; Popovych et al., 2012), was less effective at inhibiting
aggregation of human IAPP at a phospholipid interface (Engel
et al., 2012).
Here, we review the influence of surfaces in driving and stabi-
lizing protein aggregation with a specific emphasis on lipid mem-
branes. We will initially focus on Aβ as an illustrative example, and
then quickly review some interesting features of the interaction of
other select amyloid-forming proteins with surface interfaces.
THE AGGREGATION OF Aβ ON SOLID SURFACES
The ordered aggregation of Aβ into neuritic plaques is one of
the major hallmarks of AD. Aβ is a secreted peptide derived
from the endoproteolysis of the amyloid precursor protein
(APP), a receptor-like transmembrane protein, and is ubiquitously
expressed in neural and non-neural cells. Successive cleavage of
APP by β-secretase and γ-secretase results in the release of an
intact Aβ peptide. Aβ contains a portion of APP’s transmem-
brane domain, as well as an extracellular portion, resulting in
an amphiphilic peptide ∼39–43 residues in length. The Aβ com-
ponent of amyloid plaques found in the diseased brain consist
primarily of two versions of the peptide, which are 40 and 42
amino acids long [Aβ(1–40) and Aβ(1–42) respectively]. Aβ(1–
42) aggregates more quickly than Aβ(1–40) and is thought to play
a major role in AD (Jarrett and Lansbury, 1993). The amphiphilic
nature of Aβ is thought to drive its aggregation and may play
an important role in its interaction with solid surfaces and abil-
ity to insert and/or penetrate lipid membranes (Lansbury and
Lashuel, 2006; Williams and Serpell, 2011). The extra addition
of two hydrophobic residues in Aβ(1–42) may also lead to varia-
tions in the interaction of this peptide with surfaces compared to
Aβ(1–40).
Hydrophobic Teflon surfaces can be considered mimics of the
non-polar plane of lipid membranes. While both Teflon and Aβ
carry a negative charge at physiological pH, protein dehydration
effects lead to substantial adsorption of Aβ at pH 7(Giacomelli
and Norde, 2003). Aβ(1–40) and Aβ(1–42) adsorption to Teflon
particles increased aggregation and fibrillogenesis (Linse et al.,
2007). Adsorption of Aβ to another hydrophobic surface, highly
ordered pyrolytic graphite, results in extended aggregate formation
in a nucleation dependent manner (Kowalewski and Holtzman,
1999). Using a variety of surfaces with tunable hydrophobicity
or hydrophilicity (as well as supported lipid bilayers), weakly
adsorbed peptides with two-dimensional diffusivity were found
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to be critical precursors to surface growth of Aβ(1–42) fibrils
(Shen et al., 2012). As the adsorption of Aβ on highly hydrophilic
surfaces was negligible, fibril growth was inhibited on such sur-
faces. On highly hydrophobic surfaces, the two-dimensional dif-
fusion of Aβ along the surface was too low, also inhibiting fib-
ril formation. It appears that surface properties that promote
weak adsorption of Aβ to the surface and maintain translational
mobility result in local concentrations of Aβ due to confinement
within the plane of the surface, allowing for fibril formation
at a concentration far below the critical concentration observed
in bulk solutions. The adsorption of Aβ to hydrophilic silica
surfaces is pH dependent, occurring at pH 4 and 7 when Aβ
has an overall positive charge (Giacomelli and Norde, 2005),
suggesting a vital role of electrostatics on Aβ‘s adsorption to
surfaces.
Due to the ability of AFM to be operated in solution and track
the formation and fate of individual aggregates with time on sur-
faces (Goldsbury et al., 1999), the impact of surface chemistry
on the morphology of Aβ aggregates has been extensively studied
with this technique. On mica, a hydrophilic surface, Aβ(1–40)
(Blackley et al., 2000) and Aβ(1–42) (Kowalewski and Holtz-
man, 1999) form small, highly mobile oligomeric aggregates that
organize into extended pre-fibrillar aggregates that continually
elongate with time (Figure 2A). These aggregate structures are
similar in morphology to those formed in bulk solution from
similarly prepped Aβ stocks (Kowalewski and Holtzman, 1999;
FIGURE 2 | Aβ aggregation is modulated by the presence of chemically
distinct solid surfaces. (A) On highly ordered pyrolytic graphite, Aβ
aggregates into extended nanoribbons that are epitaxially ordered on the
surface. The distinct orientation of Aβ aggregates on graphite is attributed to
the optimization of the contact between the peptide and underlying
hydrophobic carbon lattice. (B) On a negatively charged, hydrophilic mica
surface, Aβ forms discrete oligomers that maintained some lateral mobility
along the plane of the surface. These oligomers could organize into elongated
protofibrillar structures. Schematic representations of the structure of each
surface (graphite and mica) are provided under each image.
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Legleiter and Kowalewski, 2004). However, Aβ(1–42) aggregates
into morphologically distinct structures on a graphite surface
(Figure 2B), forming extended nanoribbons with heights of ∼1–
1.2 nm and widths of ∼18 nm (Kowalewski and Holtzman, 1999).
These dimensions suggest that Aβ adopts a fully extended β-sheet
conformation perpendicular to the long axis of the nanoribbons.
These nanoribbons elongated with time, organize themselves into
parallel, raft-like structures with a preferential alignment along
the graphite lattice. Aβ adsorbs to and aggregates on surfaces
functionalized with methyl, carboxyl, or amine groups; how-
ever, aggregate morphology and surface affinity is dependent on
the specific surface chemistries (Moores et al., 2011). Hydropho-
bic surfaces promote formation of spherical amorphous clusters;
charged surfaces promote the formation of protofibrils (Moores
et al., 2011). Studies of the aggregation of Aβ peptides contain-
ing single point mutations on mica further support the notion
that electrostatics play an important role in Aβ adsorption and
aggregation on surfaces (Yates et al., 2011). These mutations are
clustered around the central hydrophobic core of Aβ (E22G Arc-
tic mutation, E22K Italian mutation, D23N Iowa mutation, and
A21G Flemish mutation) and are associated with familial forms of
AD. In bulk solution and under identical preparatory conditions,
these Aβ mutants form aggregated species that were morpho-
logically similar to those of Wild Type Aβ; however, on a mica
surface the aggregates differ in morphology (Figure 3). While Wild
Type Aβ forms oligomers and putative protofibrils on mica simi-
lar to other previously described studies, Arctic Aβ aggregate into
extended, fibrillar aggregates on mica that orient on the surface
similar to the previously described Wild Type Aβ aggregates on
graphite. However, the dimensions of the Arctic Aβ aggregates
on mica indicate they most likely contain a β-turn as opposed
to the fully elongated Wild Type Aβ nanoribbons on graphite.
Italian Aβ, which replaces a negatively charged residue with a
positive one, adsorbs quickly to mica and predominantly forms
oligomeric aggregates reminiscent of those formed by wild type
Aβ on mica. However, there was a small percentage of Italian Aβ
aggregates similar in morphology to those formed by Arctic Aβ
on mica.
THE INTERACTION OF AβWITH LIPID SURFACES
While studies on model surfaces can provide mechanistic detail
on how solid interfaces alter and/or promote Aβ aggregation,
ultimately, pathological protein aggregation occurs in a cellular
environment, dictating the need to study protein-misfolding and
aggregation on more physiologically relevant surfaces. This is not
to say that studies on solid surfaces are irrelevant. For example,
the aforementioned dependence on lateral mobility of Aβ on a
surface being critical in fibril formation was directly extended to
lipid surfaces as well (Shen et al., 2012). This phenomenon could
be important in light of single molecule studies demonstrating
that Aβ inserted into anionic lipid membranes demonstrate high
lateral mobility until aggregating into oligomers (King et al., 2012).
It has been hypothesized that a potential pathway for Aβ tox-
icity may lie in its ability to modulate lipid membrane function.
This hypothesis is based on the observation that Aβ bears a por-
tion of the APP transmembrane domain. Thus, elucidating the
interaction between Aβ and membrane lipids could be critical in
understanding potential pathways of Aβ toxicity, especially given
the results of studies that demonstrate that changes in membrane
composition occur in AD along with the association with plaques,
tangles, and neuritic dystrophy. Importantly, it has often been
observed that exogenously added Aβ will selectively bind a subset
of cells in an apparent homogenous population of cells in culture
(Lacor et al., 2004; De Felice et al., 2008). Such an initial cellu-
lar binding event may play a critical role in toxic mechanisms
and cell to cell propagation of disease. This cell selectivity may be
influenced by the presence of specific lipid components or mem-
brane properties (Okada et al., 2007; Wakabayashi and Matsuzaki,
2007; Lin et al., 2008). Once Aβ aggregation begins in or near
a membrane, the potential toxic mechanism include disruption
of the bilayer structure, changes in bilayer curvature, and/or the
creation of membrane pores or channels (Arispe et al., 1993a,b;
FIGURE 3 | Point mutations in Aβ(1–40) modulate aggregate morphology
in the presence of a mica surface. Using solution AFM, the aggregation of
Wild Type, Arctic (E22G), and Italian (E22K) Aβ was monitored on a mica
surface (Aβ concentration was 20µM for all experiments). 5µm×5µm
images are presented in 3D with indicated zoomed in areas of 1µm×1µm
shown in 2D. (A) Wild Type Aβ formed a large population of oligomers (red
arrows) and highly curved, elongated protofibrils (yellow arrows) with
aggregate heights of ∼3–5 nm similar to presented in Figure 2. (B) Arctic Aβ
formed rigid, branched, and highly ordered fibrillar aggregates (blue arrows)
along the crystallographic lattice of mica with aggregate heights of ∼2–5 nm
along the contour. These Arctic Aβ aggregates morphologically distinct from
those formed by Wild Type Aβ. (C) Italian Aβ predominately aggregated into
small oligomers (2–3 nm tall, red arrows) that coalesced into larger protofibrils
(yellow arrows), in a similar fashion to Wild Type Aβ; however, a small number
of rigid, elongated “Arctic-like” fibrillar aggregates of Italian Aβ also formed
(blue arrow).
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McLaurin and Chakrabartty, 1996, 1997; Mirzabekov et al., 1996;
Gorbenko and Kinnunen, 2006; Figure 4). The majority of stud-
ies on membrane-mediated fibrillogenesis have been undertaken
with model systems including amyloidogenic peptides or proteins
and lipid vesicles or supported bilayers of varying composition
(Terzi et al., 1997; Lindstrom et al., 2002; Bokvist et al., 2004; Sparr
et al., 2004). These studies often point to the importance of the
chemical nature of membrane lipids and the mode of protein–lipid
interactions in determining fibrillogenic properties of membrane
bound Aβ. Lipids can also stabilize toxic protofibrils and even
revert mature fibrils into such toxic species (Martins et al., 2008),
providing another potential role for lipid surfaces in toxicity.
A large number of biophysical techniques have been applied
in understanding the specific interactions between lipid mem-
branes and Aβ. Due to the ability to control bilayer composition,
biomimetic unilamellar vesicles have been extensively used to elu-
cidate the interaction between Aβ and membranes (Williams et al.,
2010). Simple vesicles comprised of a single lipid component, soy-
bean PC, have been used to demonstrate that the presence of
neutral PC delays the characteristic lag time to initiate Aβ aggre-
gation in a lipid concentration-dependent manner (Sabate et al.,
2005). Lipids can also induce changes in the secondary structure
of Aβ, as CD studies demonstrated that a variety of lipids induce a
transition from an α-helical to β-sheet structure in Aβ(McLaurin
and Chakrabartty, 1997). As with solid surfaces, the charge of
the lipid membrane surfaces, determined by the headgroups of
phospholipids, dictate the extent of Aβ/membrane association due
to electrostatic considerations. For example, similarly prepared
Aβ(1-40) displays a stronger affinity to liposomes comprised of
POPG compared to those comprised of POPC, with only the
association with POPG enhancing the rate of Aβ aggregation
(Kremer and Murphy, 2003). Freshly prepared Aβ(1–40) prefer-
entially binds negatively charged PG membranes and composite
membranes containing negatively charged lipids in comparison to
neutral membranes; however, the relative affinity for fibril aggre-
gates of Aβ with these lipid membranes is altered (Lin et al., 2007).
Allowing Aβ(1–40) to form fibrils causes the affinity for negatively
charged membranes to be smaller compared to the affinity for neu-
tral membranes, suggesting that Aβ aggregation state can further
modulate the interaction with lipid surfaces.
A potential mechanism for amyloid-forming proteins, such as
Aβ, is their ability to alter membrane structure and integrity, lead-
ing to permeation of cellular membranes (Figure 4). Detergent-
like effects arise from the amphiphilic nature of Aβ, leading to
reduced membrane surface tension leading to membrane thin-
ning and hole formation (Hebda and Miranker, 2009). Several
AFM studies performed in solution have provided valuable insight
into the aggregation of Aβ on a variety of model lipid mem-
branes, leading to altered membrane morphology. The interaction
of Aβ(1–40) with bilayers formed from total brain lipid extract
(TBLE) revealed that Aβ(1–40) will partially insert into bilayers,
growing into small fibers (Yip and McLaurin, 2001). In the same
study, larger fiber-like structures associated with disruption of the
bilayer morphology and integrity were observed as measured by
increased surface roughness and formation of holes, respectively.
Large fibrils were often highly branched and associated with edges
of disrupted bilayer. The TBLE bilayers also aided in nucleation
and enhancement of fibril growth. Interestingly, preformed fib-
rils were not capable of disrupting the TBLE bilayers, which may
indicate that the act of aggregation, that is pre-fibrillar aggre-
gates, may be key in Aβ-induced membrane disruption. Similar
experiments exposing DMPC bilayers to Aβ(1–40) resulted in the
FIGURE 4 | Schematic representations of potential mechanisms of
amyloid/lipid association. (A) A schematic representation of simplified,
undisrupted bilayer is presented. This bilayer structure can be perturbed by (B)
amyloid-protein insertion or (C) association of amphiphilic α-helices
lipid-binding domains. Such scenarios could lead to membrane thinning and
non-specific membrane leakage. (D) Many amyloid-forming proteins have
been shown to form pore-like structures that can act as unregulated
ion-selective channels.
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formation of globular aggregates that were associated with small
holes in the bilayer, whereas, fibril growth and/or extensive bilayer
disruption was not observed. Aβ(1–42) demonstrated a differ-
ent interaction/aggregation pattern on TBLE bilayers (Yip et al.,
2002). Discrete molecules of Aβ(1–42) could be detected on the
surface that were replaced by distinctly larger aggregates with time.
However, bilayer defects were rarely detected upon exposure to
Aβ(1–42). Point mutations in Aβ(1–40) also altered the aggrega-
tion on and ability to disrupt TBLE bilayers (Figure 5; Pifer et al.,
2011). These same point mutations were shown to cause poly-
morphic aggregation of Aβ on mica. Aggregation in the presence
of TBLE bilayers resulted in a variety of polymorphic aggregates
in a mutation dependent manner and a variable ability to disrupt
bilayer morphology/integrity. Such results highlight the potential
role electrostatic and hydrophobic properties of Aβ play in its
ability to bind, insert, and potentially disrupt lipid membranes.
Another proposed toxic mechanism points to Aβ‘s ability to
alter cellular ion concentrations, calcium in particular, through
the formation of membrane pores (Figure 4D). Initial evidence
for this scenario came from the observation that PS bilayers that
had Aβ(1–40) directly incorporated into them displayed linear cur-
rent/voltage relationships in symmetrical solutions (Arispe et al.,
1993a). Further evidence for this scenario was provided by studies
on phospholipid vesicles that had either Aβ(1–42) (Rhee et al.,
1998) or Aβ(1–40) (Lin et al., 1999) directly incorporated into
them. In both cases, these vesicles stiffened in the presence of cal-
cium, due to calcium ion-induced charge–charge repulsion inside
the vesicles, binding of calcium to lipids and proteins, and an
enhanced efficiency of lipid–protein interactions. This increased
stiffness of the vesicles could be blocked by pretreatment with
anti-Aβ antibodies, Tris, or zinc, all of which would block puta-
tive calcium channels. Reconstituting Aβ(1–42) with a planar lipid
bilayer resulted in the formation of multimeric channel-like struc-
tures with symmetries suggesting tetramer or hexamer pore-like
structures of Aβ(Lin et al., 2001; Quist et al., 2005). The forma-
tion of a variety of similar aggregate structures in lipid membranes
have also been demonstrated computationally (Capone et al., 2012;
Tofoleanu and Buchete, 2012).
Similar impacts on membranes due to exposure to Aβ have
been detected in cellular models. Cells exposed to Aβ(1–40),Aβ(1–
42), and Aβ(25–35) on endothelial cells undergo morphological
changes and cell disruption, with the highest sensitivity to Aβ(1–
42) (Zhu et al., 2000). While cell disruption was induced by
nanomolar concentrations of Aβ(1–42), micromolar concentra-
tions of Aβ(1–40) were required to trigger similar effects. Sim-
ilar observations were reported for fibroblasts in the presence of
nanomolar Aβ(1–42), as morphological changes along the periph-
ery of the cell were observed that could be blocked by anti-Aβ
antibodies, zinc, and the removal of calcium (Zhu et al., 2000).
Protofibrils and low molecular weight oligomers of Aβ can alter
the electrical activity of neurons and reproducibly induced toxicity
in mixed brain cultures in a time- and concentration-dependent
manner, suggesting changes in membrane integrity and depolar-
ization (Hartley et al., 1999). Aβ peptides induce ion channel-like
ion flux in model lipid membranes and neuronal membranes
independent from the ability of Aβ to modulate intrinsic cel-
lular ion channels or transporter proteins (Capone et al., 2009)
Even intracellular forms of Aβ can alter the electrophysiological
properties of cultured human primary neurons (Hou et al., 2009).
Aβ(1–42) oligomers form single ion channel permeable to Ca2+ in
oocytes are highly toxic and not attributable to endogenous oocyte
channels (Demuro et al., 2011).
The discussed potential mechanism of Aβ toxicity associ-
ated with lipid membranes are not exhaustive, nor are they
mutually exclusive. Aβ-induced membrane disruption of POPC,
POPOC/POPS/gangliosides, and TBLE systems occurred in a two-
step process (Sciacca et al., 2012). The initial step involved the for-
mation of ion-selective pores, followed by non-specific fragmenta-
tion of the lipid membrane due to fibrillization. This demonstrates
that different mechanism of membrane disruption may be asso-
ciated with specific stages of aggregation. Large unilamellar lipid
vesicles (LUVs) encapsulating self-quenching fluorescent dyes can
FIGURE 5 | Point mutations in Aβ influence peptide aggregation in the
presence of total brain lipid bilayers. Using solution AFM, aggregation
of Wild Type, Arctic (E22G), or Italian (E22K) Aβ in the presence of
supported TBLE bilayers was monitored (Aβ concentration was 20µM for
all experiments). 3D images are presented (4µm× 4µm and
6µm×6µm) with indicated zoomed in areas of 1µm×1µm and
2µm×2µm shown in 2D. (A) With time, Wild Type Aβ aggregated into
discrete oligomers and fibrils that were associated with regions of the
bilayer with perturbed morphology (an increase in surface roughness). (B)
While many small oligomers of Arctic Aβ were observed on the bilayer,
highly curved fibrils that were associated with membrane disruption were
the dominant aggregate species. These Arctic Aβ fibrils were
morphologically distinct from fibrils observed for Wild Type Aβ. (C) While
Italian Aβ also formed similar oligomers compared Wild Type and Arctic Aβ,
large patches of disrupted bilayer morphology developed that may be
associated with distinct fibril aggregates.
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be used as reporters of membrane disruption and leakage. Such
systems have been used to elucidate the ability of Aβ to disrupt
membrane integrity. Upon exposure of LUVs comprised of DMPC
and containing calcein to Aβ(1–42) oligomers, the LUV structure
is disrupted, allowing leakage of the dye, but preformed fibrils have
a decreased ability to disrupt LUVs (Williams et al., 2010). How-
ever, the oligomers that interacted with the DMPC LUVs formed
fibrils, suggesting that the aggregation process may actually play a
role in membrane disruption.
A variety of studies indicate the ability of Aβ to bind mem-
branes is highly dependent on the presence of specific lipid com-
ponents, i.e., cholesterol (Yip et al., 2001; Reiss et al., 2004; Yu
and Zheng, 2012), sphingolipids (van Echten-Deckert and Wal-
ter, 2012), gangliosides (McLaurin and Chakrabartty, 1996), and
neutral or charged phospholipids (McLaurin and Chakrabartty,
1997; Sabate et al., 2005, 2012). This may be due to specific chemi-
cal/electrostatic interactions between membrane components and
Aβ and/or the mechanical properties of the bilayer associated with
their specific composition. For example, altering the cholesterol
content of supported TBLE bilayers changes Aβ aggregation on
membranes. Aβ(1–40) induced bilayer disruption and its ability to
form fibrils on the bilayer was strongly dependent on cholesterol
content of the supported bilayers (Yip et al., 2001). Cholesterol
depletion of bilayers inhibited the ability of Aβ(1–40) to perturb
bilayer structure. When Aβ(1–40) was added to TBLE bilayers that
had been enriched with 10% exogenous cholesterol, discrete Aβ(1–
40) peptides appeared on the bilayer within ∼30 min. Eventually,
ring-like Aβ(1–40) structures with diameters of 55–80 nm as well
as short fibrils and small aggregates were observed on the choles-
terol enriched bilayer, but no membrane disruption was observed.
At higher cholesterol content (30% of the total lipid), these Aβ(1–
40) aggregates were not observed. The ability of Aβ(1–40) to
disrupt the TBLE bilayers with varying amounts of cholesterol
correlated with bilayer fluidity, indicating that decreased fluidity
(modulated by cholesterol content) of the membrane somehow
enhanced the interaction between the bilayer and Aβ. Simulation
of POPC bilayers containing different mole fractions of cholesterol
demonstrate that cholesterol induces changes in bilayer proper-
ties, i.e., membrane structure, dynamics, and surface chemistry,
that cause increased bilayer thickness, ordering of hydrophobic
chains, surface hydrophobicity, and decreased lipid mobility (Yu
and Zheng, 2012). These effects promoted the binding of Aβ(1–42)
to the model POPC lipid bilayers.
Cholesterol is also critical in the insertion of oligomeric forms
of Aβ(1–42) into POPC membranes (Ashley et al., 2006). With
DOPC model bilayers, the addition of cholesterol acts as a target
for the binding of Aβ to the membrane (Drolle et al., 2012). AFM
studies further illustrate that the alteration of bilayer mechani-
cal properties induced by lipid composition impact the ability of
Aβ to bind membranes, by demonstrating that astrocyte secreted
lipoprotein particles containing different isoforms of apolipopro-
tein E (apoE), of which the apoE4 allele is a major risk factor
for the development of AD, protect TBLE bilayers from Aβ(1–
40) induced disruption (Legleiter et al., 2011). The apoE4 allele
was less effective in protecting these bilayers from Aβ(1–40) com-
pared with their apoE3 counterparts, and further analysis revealed
that this was due to the varying ability of the lipoprotein particles
containing different alleles of apoE to modulate the fluidity of
bilayers by acquiring bilayer components (most likely cholesterol
and/or oxidatively damaged lipids). There is evidence that pep-
tide/membrane affinity in vascular cells can also be related to the
ability of cholesterol to modulate membrane fluidity and struc-
ture (Subasinghe et al., 2003). Other cell culture assays, using
PC-12 and SH-SY5Y cells, demonstrated that depleting cells of
cholesterol increased the cellular binding of Aβ(1–40) (Yip et al.,
2001).
While the mechanical properties of bilayers can influence their
susceptibility to Aβ binding, once Aβ binds a membrane, this asso-
ciation may also alter the mechanical properties of the membrane,
leading to dysfunction. Such a scenario is plausible considering
the observed morphological changes associated with lipid mem-
branes exposed to Aβ(Yip et al., 2002; Legleiter et al., 2011; Pifer
et al., 2011). Anisotropy studies with POPC and POPG lipid mem-
branes demonstrated that monomeric Aβ had initially little impact
on bilayer fluidity; however, oligomers were able to decrease bilayer
fluidity (Kremer et al., 2000). Furthermore, oligomers prepared at
pH 6 had a larger impact on bilayer fluidity compared to oligomers
that formed at a neutral pH, suggesting that distinct, polymorphic
oligomers were formed under the different conditions (Kremer
et al., 2000). Studies performed on supported phospholipid mem-
branes revealed that exposure to Aβ modifies morphology and
local mechanical properties of bilayers, reducing the force required
to break through the membrane with an AFM probe (Dante et al.,
2011). The lysis tension of unilamellar vesicles containing oxys-
terols are altered by exposure to nanomolar concentration of Aβ
peptides (Kim and Frangos, 2008). Collectively, these results sug-
gest Aβ can negatively impact the mechanical integrity of lipid
membranes.
The major risk factor associated with AD is age. Age-related
changes in membrane composition and/or physical properties may
facilitate an increased cellular susceptibility to Aβ cytotoxicity. For
example, both enhanced cellular cholesterol content (Wood et al.,
2002; Cutler et al., 2004; Panchal et al., 2010) and oxidative dam-
age (Chen and Yu, 1994; Choe et al., 1995) are associated with
aging, decreased fluidity of membranes, and AD. Oxidative dam-
age of polyunsaturated fatty acids, in general, increase lipid bilayer
rigidity as a result of increased steric hindrance restricting the
movement of lipid acyl chains (Choe et al., 1995; Choi and Yu,
1995). Furthermore, Aβ oligomers display preferential accumu-
late at oxidatively damaged plasma membranes of cells (Cecchi
et al., 2007), and there is evidence of enhanced oxidative damage
in AD brains (Williamson et al., 2008; Ansari and Scheff, 2010).
Such studies suggest that altered membrane mechanics play a role
in facilitating Aβ/lipid interactions.
SURFACE AGGREGATION OF OTHER AMYLOID-FORMING
PROTEINS
Surfaces can also modulate the aggregation of other amyloid-
forming proteins associated with neurodegenerative diseases.
Specifically, these proteins may also alter membrane homeosta-
sis, presumably via similar mechanisms as described for Aβ. Here
we will briefly discuss some features of the interaction of other
amyloid-forming proteins: htt, α-syn, apolipoprotein C-II, and
prions. Many studies of the aggregation of these two proteins
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have focused on lipid vesicles or organelles, which have mem-
branes comprised predominately of lipids, and these studies fur-
ther highlight how aggregation can be modulated by membrane
composition.
THE INTERACTION OF α-syn WITH SURFACES
Parkinson’s disease is a neurodegenerative disease caused by the
sporadic misfolding and aggregation of the protein α-synuclein
(α-syn) leading to the appearance of inclusions termed Lewy bod-
ies. Electron microscopy (EM) and ex situ AFM have shown that,
while a heterogeneous population of oligomers, protofibrils, and
annular aggregates exists (Conway et al., 2000; Apetri et al., 2006),
over time the predominant aggregate species are fibrillar (Conway
et al., 1998; Narhi et al., 1999; Apetri et al., 2006). While Lewy bod-
ies have long been known to be comprised of fibrils (Duffy and
Tennyson, 1965) it is now widely believed that pre-fibrillar and pre-
Lewy body inclusions aggregates are responsible for disease. The
fragmentation of the Golgi apparatus, for example, corresponds
to the appearance of protofibrils, rather than fibrils (Gosavi et al.,
2002). This notion that pre-fibrillar aggregates are the cause of
disease is supported by dementia with Lewy bodies patient brains
lysates containing elevated levels of α-syn oligomers (Paleologou
et al., 2009) compared to control and AD patient brains. Toxicity
in cell models is usually displayed without fibrillar or protofibrillar
species, but rather a 54–83 kDa aggregate, perhaps comprised of
17 kDa oligomers, that appears to mediate neurotoxicity (Xu et al.,
2002). Transgenic mice, unlike human patients, exhibited neu-
rodegeneration and inclusions comprised of fine granular material
and clear vacuoles, not fibrils (Masliah et al., 2000). Furthermore,
appearance of Thioflavin T (ThT) reactive aggregates have been
shown to correspond with decreased fluidity of lipid acyl chains
in membranes (Smith et al., 2008).
Surface stabilized α-syn aggregates have been observed by
in solution AFM studies, where fibrillar sheets grew in length
along two directions 120˚ from each other reflecting the pseudo-
hexagonal surface geometry of muscovite mica. Altering the sur-
face substrate from mica, a hydrophilic surface, to highly order
pyrolytic graphite, a hydrophobic surface, impeded sheet forma-
tion, demonstrating a specific surface dependent growth mecha-
nism (Hoyer et al., 2004). This is contrary to what has been seen
in EM and ex situ AFM studies in which α-syn is aggregated in
bulk solution. In these studies, α-syn forms oligomers and fibrils
without any discernible directionality (Conway et al., 2000).
In pre-synaptic termini, α-syn exists in both free and plasma
membrane or vesicle bound states (McLean et al., 2000). Densito-
metric analysis of rat brain fractionation demonstrated that∼15%
α-syn in the supernatant is membrane bound (Lee et al., 2002).
Homozygous deletions of α-syn in mouse models and overexpres-
sion of α-syn in a neuronal cell line corresponded with changes in
membrane fluidity and cellular fatty acid uptake and metabolism
(Sharon et al., 2003; Castagnet et al., 2005; Golovko et al., 2005).
Similarly, α-syn has been shown to have a strong interaction with
synthetic anionic phospholipid vesicles (Davidson et al., 1998; Jo
et al., 2000; Ramakrishnan et al., 2003), crude brain vesicles, cellu-
lar membranes, lipid rafts, and lipid droplets (Jensen et al., 1998;
McLean et al., 2000; Cole et al., 2002; Fortin et al., 2004). EPR
studies have demonstrated that the α-syn helix extends parallel
to the curved lipid (Jao et al., 2008), while electron microscopy
experiments note α-syn’s ability to tubulate vesicles (Varkey et al.,
2010). Ex situ AFM studies of PG vesicles exposed to α-syn lead
to membrane fragmentation (Volles et al., 2001) and in solution
AFM experiments of α-syn aggregation on mica supported lipid
bilayers demonstrate that α-syn association leads to bilayer dis-
ruption and eventual fibril formation on the exposed mica surface
(Jo et al., 2000). This interaction with lipid structures is believed
to be directed by the first N-terminal 60 amino acids of α-syn,
which contains an amphipathic α-helix structurally similar to
apolipoproteins-binding domains (Clayton and George, 1998).
Thus, the first 60 amino acids of α-syn causing subcellular local-
ization may lead to 1) an increase in local α-syn concentration
and nucleation sites or 2) the α-helical structure of the mem-
brane bound α-syn might impede misfolding into high-ordered
aggregates. Supporting the first hypothesis, FTIR and far-UV CD
studies demonstrate that aggregation of α-syn depends on the
proximity of the membrane; amorphous aggregates were formed
on or close to membranes whereas fibrillar aggregates were formed
distant to membranes (Munishkina et al., 2003). Fluorescence
and AFM experiments with polytetrafluroethylene balls and α-syn
also highlight that aggregate formation is dominated by reactions
at hydrophobic interfaces, like lipid membranes (Pronchik et al.,
2010). Similarly, fluorescence studies on supported lipid bilayers
demonstrate that α-syn clustering on membranes is a function of
anionic lipid and/or protein concentration (Pandey et al., 2009).
Double electron–electron resonance studies reveal well-defined α-
syn aggregates with lipids that could form part of larger aggregates
and serve as nucleation sites (Drescher et al., 2010). The second
hypothesis that α-helical membrane bound α-syn impedes aggre-
gation into higher ordered aggregates, is supported a fluorescence
resonance energy transfer study, where membrane binding alters
the tertiary conformation of α-syn such that oligomerization is
inhibited (Narayanan and Scarlata, 2001). However, it is important
to note that the two hypotheses may not be mutually exclusive. It is
possible that α-syn binding to a membrane stabilizes and nucleates
a toxic aggregate specie.
Circular dichroism studies have also hinted at surface altered
aggregate species as α-syn in PBS is in a random coiled sec-
ondary structure, whereas α-syn in the presence of POPC/POPS
small unilamellar vesicles (SUVs) formed an α-helical structure.
These studies further demonstrated that α-syn aggregation was
not an effect of surface curvature as POPC/POPS multilamel-
lar vesicles (MLVs), POPC/POPI, and POPC/POPA SUVs do not
result in α-syn α-helical structure, whereas with the addition of
PE to POPC/PI and POPC/POPA SUVs α-syn’s α-helical content
increased (Jo et al., 2000). These studies suggest that surface mem-
brane composition plays a role in stabilizing aggregates. Stabilized
annular aggregates have been found in in vitro studies and human
brain samples. This stabilized pore-like structure is hypothesized
to lead to membrane ion leakage (Lashuel et al., 2002; Pount-
ney et al., 2004). Thus, surface stabilized aggregates, such the
membrane stabilized annular aggregates, may be one key toward
understanding the mechanism of toxicity in PD.
THE INTERACTION OF HUNTINGTIN WITH SURFACES
Huntington’s disease is another neurodegenerative disease caused
by a polyQ expansion within exon1 htt. The length of the polyQ
domain is intimately correlated to age of onset and severity of
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disease (Snell et al., 1993; Penney et al., 1997; Tobin and Signer,
2000). Inclusion bodies, the hallmark of disease, once thought
to be the toxic species, have been shown by a survival analysis
to potentially have a beneficial rather than pathogenic response
to htt aggregation (Arrasate et al., 2004). AFM experiments with
both GST-fusion htt exon1 proteins and synthetic polyQ peptides
demonstrate a heterogeneous and complex aggregation mecha-
nism, including oligomers, fibrils, annular aggregates, and inclu-
sions, in which antibodies detect numerous different conforma-
tions of these aggregates (Legleiter et al., 2009, 2010). Analytical
size exclusion chromatography experiments have demonstrated
that flanking sequences of the polyQ domain alter aggregation
rates considerably. Specifically, in bulk solution the first 17 N-
terminal amino acids accelerate aggregation while the a C-terminal
polyproline (polyP) domain retards aggregation rates (Thakur
et al., 2009). Different types of HD models have shown that in
neurons, both normal and mutant htt proteins localize to several
subcellular compartments, such as endosomes, pre-synaptic, and
clathrin-coated vesicles, and dendritic plasma membrane (Harjes
and Wanker, 2003). Furthermore, htt inclusion bodies developed
in cell lines expressing large N-terminal htt fragments incorporate
multi-vesicular membranes, autophagosomes, and mitochondria
into their surfaces (Kegel et al., 2000; Qin et al., 2004).
Immunohistochemical studies and subcellular fractions have
also highlighted the fact the htt is enriched in membrane-
containing fractions (Gutekunst et al., 1995). In fact, ∼50%
of endogenous htt distributes with membranes after subcellu-
lar fractionation of neuron-like clonal striatal cells (Kegel et al.,
2005). Thus, the wide subcellular localization and membrane-
incorporated aggregates suggest that there is a strong htt inter-
action with lipid bilayers, which may be directed by the first 17
amino acids on the N-terminus of htt exon1. This domain appears
to adopt a highly conserved amphipathic α-helix with membrane
binding properties (Atwal et al., 2007), which may be facilitated
by the polyP domain on the C-terminal side of the polyQ domain
(Qin et al., 2004). Similar to PD, subcellular localization of htt
may lead to a local increase in htt concentration creating aggrega-
tion nucleation sites or stabilization of the α-helical conformation
may actually stabilize specific aggregate species that are transiently
formed in bulk solution. It is possible that htt association to
membranes nucleates some types of aggregation while potentially
stabilizing specific intermediates along that aggregation pathway.
Surface stabilized aggregates of simple polyQ peptides have
been observed via in solution AFM studies that demonstrated that,
while the majority of peptide formed extensive fibrillar networks,
discrete oligomers formed on a mica surface (Legleiter et al., 2010;
Burke et al., 2011). These studies are contrary to previous assump-
tions based on bulk solution experiments that aggregation of pure
polyQ peptides proceeded directly from monomer to fibril with-
out oligomeric intermediates (Chen et al., 2002a,b). Similar to
α-syn, htt has also been observed by CD to alter its structure in the
presence of POPC and POPS:POPC SUVs, both compositions of
endoplasmic reticulum (ER) and ER derived vesicles (Atwal et al.,
2007). These studies were able to show that while htt does have
α-helical content in free solution, α-helical content is altered in
the presence of SUVs. Interestingly, although no structural data
was provided, densitometry data from Western blots were able
to demonstrate that htt/lipid interaction is modulated by mem-
brane composition and polyQ length (Kegel et al., 2009). Here,
increased polyQ length had a preferential association with multi-
valent phospholipids. Stabilized oligomers have been identified to
be associated with mitochondrial structural proteins in HD patient
brains. Here, it is believed that the oligomeric species lead to mito-
chondrial fragmentation, abnormal mitochondrial dynamics, and
oxidative DNA damage (Shirendeb et al., 2011). Surface stabi-
lized htt aggregates, such as mitochondrial stabilized oligomeric
species, may lead to understanding potential toxic mechanisms
and therefore therapeutic targets.
Posttranslational modifications of htt further modify its traf-
ficking and interaction with membranous cellular surfaces.
Sumoylation of the first 17 N-terminal amino acids in htt exon1
leads to its being trafficked to the nucleus (Steffan et al., 2004). This
sumoylation of mutant htt also increases soluble diffuse aggregates
that elicit greater cytotoxicity and neurotoxicity in HD Drosphila
models (Steffan et al., 2004). More specifically, when Rhes, a pro-
tein selectively localized in the striatum that increases sumoylation
in transgenic mice, is overexpressed in mutant htt knock-in stri-
atal cells, cell survival is reduced by 60% whereas there is no effect
with wild type htt (Subramaniam et al., 2009). Similarly, phospho-
mimetic mutations at serine 13 and 16 have been shown to alter
the kinetics of aggregation by reducing fibrillization while accu-
mulating alternative aggregates (Gu et al., 2009). YAC128 mouse
models demonstrated that ganglioside GM1 treatment induced
phosphorylation at serines 13 and 16 resulting in a restoration
of normal motor behavior (Di Pardo et al., 2012). Furthermore,
structural studies have determined that phosphorylation of serines
13 and 16 inhibit the first 17 N-terminal amino acids’ amphipathic
α-helix, altering the localization of htt within cells (Atwal et al.,
2011). Collectively, these posttranslational modifications of the
N-terminal domain modulate its lipid-binding properties and the
cellular trafficking of htt.
THE INTERACTION OF apoC-II WITH SURFACES
Not all amyloid diseases are neurodegenerative in nature, and
insights into the ability of lipid association to promote specific
aggregation pathways and structure can be gleaned from these
systems. One such illustrative system is amyloid deposition asso-
ciated with aortic atherosclerotic lesions (Westermark et al., 1995;
Mucchiano et al., 2001; Rocken et al., 2006), which contain numer-
ous plasma apolipoproteins, such as apolipoprotein C-II (apoC-II;
Medeiros et al., 2004). Lipid stabilized conformations of apoC-II
have long been observed. CD studies have shown apoC-II exists in
a highly disordered conformation in bulk solution (Tajima et al.,
1982), whereas, in the presence of sodium dodecylsulfate, triflu-
oroethanol, and phosphatidylcholine vesicles apoC-II adopts a
helical structure (Tajima et al., 1982). Furthermore, in the absence
of lipid, TEM, and AFM studies have revealed that apoC-II forms
stable fibrillar ribbons (Hatters et al., 2000; Teoh et al., 2011) with
increased β-sheet content as measured by CD (Hatters et al., 2000),
whereas TEM and turbidity assays have demonstrated that DHPC
micelles inhibit amyloid formation while inducing α-helical for-
mation believed to be amphipathic (Hatters et al., 2001). ThT
fluorescence assays have even demonstrated that a 1:4 apoC-II60–70
peptide to D5PC lipid ratio is sufficient to inhibit fibril formation
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up to 24 h (Hung et al., 2008). In the presence of sub-micellar
phospholipid concentrations, apoC-II forms a tetrameric struc-
ture that when seeded forms apoC-II fibrils, thus indicating that
the tetramer specie is on-pathway to fibril formation (Ryan et al.,
2008).
Intriguingly, TEM and CD studies have observed apoC-II poly-
morphisms by altering the lipid environment present during fibril-
lization. Under low-lipid concentrations, two apoC-II populations
are observed in solution, which are believed to have competing
fibril assembly pathways resulting in two distinct fibril structures.
One fibril structure is believed to occur via the same pathway as
“lipid-free” conditions, resulting in the rapid formation of ribbon-
like fibrils. The second fibril structure results in a slower develop-
ment of straight fibrils and is believed to form from the remaining
population of lipid-associated apoC-II. Furthermore, the popula-
tion of ribbonlike fibrils appears to decline as the straight fibrils
are assembling, thus it is believed that apoC-II is able to transition
from a mature ribbonlike fibril into the straight fibrillar assem-
bly pathway (Griffin et al., 2008). Therefore, the lipid stabilized
straight fibrils may be key toward understanding the toxic mech-
anism associated with atherosclerosis. The mechanisms by which
lipids trigger specific aggregate forms of apoC-II may inform us
concerning similar phenomena in neurodegenerative diseases.
THE INTERACTION OF PRIONS WITH SURFACES AND
PARALLELS WITH CELL TO CELL TRANSPORT OF
AMYLOID-FORMING PROTEINS
Of all of the neurodegenerative diseases, prion diseases (or trans-
missible spongiform encephalopathies) have long been consid-
ered unique due to their infectious nature (Prusiner and Hsiao,
1994; Prusiner, 1998; Aguzzi and Calella, 2009). Prion diseases
are caused by the posttranslational misfolding of the benign, α-
helical prion protein cellular isoform (PrPC) into an infectious
disease-related, β-sheet rich form (PrPSc; Caughey et al., 1991;
Pan et al., 1993). AFM and EM experiments using PrP proteins and
fragments demonstrate a complex aggregation mechanism involv-
ing oligomers (Serio et al., 2000), polymorphic fibrils (Anderson
et al., 2006), and amorphous aggregates (Pan et al., 1993). Prions
replicate by forcing PrPC of the host animal to adopt the PrPSc
form, and this infectious, protein-only mechanism is now widely
accepted (Soto, 2011).
As exposure to the PrPSc form occurs extracellular, the inter-
action of prions with the exterior surface of cells may play an
important role in a variety of toxic or infectious mechanisms.
Several studies point to a role for lipid membranes in the conver-
sion of PrPC to PrPSc that leads to aggregation (Stahl et al., 1990;
Sanghera and Pinheiro, 2002; Robinson and Pinheiro, 2010). The
model prion protein fragment (PrP118-135) undergoes confor-
mational and orientational changes in model POPG lipid bilayers
(Li et al., 2012). Furthermore, the interaction between prions and
cellular membranes lead directly to liposome fusion and apoptotic
cell death (Pillot et al., 1997, 2000). SDS-PAGE and subcellu-
lar fractionation studies demonstrated that PrPC is a glycosyl-
phosphatidylinositol (GPI)-anchored cell surface protein (Oesch
et al., 1985; Meyer et al., 1986), and fluorescence studies have
indicated that membrane environment alters the conformation of
recombinant PrP lacking a GPI anchor (Morillas et al., 1999), play-
ing an important role in the initial formation of the PrPSc form.
Furthermore, lipid rafts or caveola-like domains are believed to
be involved in the conformational transition of PrP (Gorodin-
sky and Harris, 1995; Vey et al., 1996). FTIR studies of PrPC
binding to lipid membranes composed of DMPC, sphingomyelin,
cerebroside, and cholesterol observed PrPC forming β-sheets at
the membrane interface as the concentration of PrPC reached a
concentration threshold (Elfrink et al., 2008). Studies using CD
spectroscopy also demonstrated that β-sheet formation in PrP106-
126 fragments is induced by the clustered negative surface charges
on a lipid membrane surface (Miura et al., 2007). Recently, an
immunofluorescence analysis of MYC-tagged PrPSc exposed to
Rocky Mountain Laboratory mouse prions was able to demon-
strate that the infectious isoform PrPSc was present primarily
located at the plasma membrane within 1 min of exposure (Goold
et al., 2011). Collectively, these studies suggest that the exterior
surfaces of cell may play a role in the initial formation of PrPSc
and its subsequent propagation.
Recently, several other amyloid-forming proteins have been
shown to have prion-like infectious properties. The ability to cir-
cumvent the lag-phase of amyloid formation by adding preformed
aggregates in a process called seeding (Jarrett and Lansbury, 1993;
Lansbury, 1997; Paravastu et al., 2006; Nonaka et al., 2010; Jucker
and Walker, 2011; Serem et al., 2011), demonstrating that such
seeds can impose aberrant structure on other proteins. Such a
phenomenon appears to play a role in the cell to cell translation of
the disease state across specific regions of the brain (Vonsattel and
DiFiglia, 1998; Braak et al., 2003; Ravits et al., 2007; Braak and Del
Tredici, 2011), and this is reminiscent of the infectious nature of
prions. Acceleration of AD has been observed in several transgenic
mouse studies by the injection of preformed Aβ aggregates, sug-
gesting that Aβ may have self-propagating conformations that can
seed aggregation in vivo (Kane et al., 2000; Meyer-Luehmann et al.,
2006; Stohr et al., 2012). A similar phenomenon has been observed
for tau (Clavaguera et al., 2009) and α-syn (Mougenot et al., 2012).
While cellular membranes may still represent a target in many toxic
mechanisms, for predominately extracellular Aβ, the ability of mis-
folded conformers to induce/seed aggregation does not necessarily
depend on cellular uptake. However, for seeding of protein aggre-
gation associated in neurodegenerative diseases associated with
intracellular inclusions/deposits, uptake of the self-propagating
conformers is necessary, and this may be facilitated by the interac-
tion with the cell membrane or other lipid-containing structures.
Cellular uptake of aggregates of several amyloid-forming proteins
has been demonstrated. Aggregates superoxide dismutase-1 asso-
ciated with ALS can penetrate cells by macropinocytosis and seed
further aggregation (Munch and Bertolotti, 2012). Pure polyQ and
htt exon1 aggregates have both been shown to penetrate mam-
malian cells, inducing aggregation (Ren et al., 2009; Trevino et al.,
2012). Experiments with cultured cells have demonstrated that
extracellular aggregates of tau are endocytosed by cells, inducing
the aggregation of intracellular tau (Frost et al., 2009; Nonaka et al.,
2010; Guo and Lee, 2011), and the propagation of tau aggregates
within the brain of a mouse model via a prion-like mechanism
has been demonstrated (de Calignon et al., 2012). The ability of
α-syn aggregates to seed intracellular aggregation in a variety of
cellular systems (Danzer et al., 2009; Hansen et al., 2011) has also
been demonstrated and mouse models (Mougenot et al., 2012) has
been demonstrated. The interaction of amyloid-forming proteins
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with cellular surfaces may also stabilize aggregates with seeding
capabilities. Such a scenario has been demonstrated for α-syn (Lee
et al., 2002).
CONCLUSION
While the aggregation of amyloid-forming proteins in bulk solu-
tion has been extensively studied, there is still much to understand
at the molecular level about protein aggregation associated with
surfaces. Of particular interest are lipid membrane surfaces, which
cannot only mediate and influence protein aggregation, but also
may be directly targeted by toxic protein aggregates. Due to the
transient nature of several aggregate species and the continuing
debate concerning specific toxic species, the mechanisms associ-
ated with the ability of surfaces, like lipid membranes, to poten-
tially stabilize (Drescher et al., 2010) or promote (Martins et al.,
2008) specific aggregates need to be further elucidated. Under-
standing these phenomenon may prove crucial in the effectiveness
of therapeutic strategies based on manipulating the aggregation
pathways of amyloid-forming proteins, as has been demonstrated
for EGCG (Engel et al., 2012). The exact mechanisms associated
with amyloid-forming proteins leading to cellular dysfunction and
death have not fully been elucidated. The ability of such proteins
to perturb membrane integrity via a variety of scenarios could
directly lead to membrane dysfunction, disrupting organelles, or
cellular homeostasis. Still, the specific aggregate species that cause
membrane destabilization are not entirely clear, and it could be
that the aggregation process itself occurring at lipid surfaces may
play a critical role in damaging membranes. It is an intrigu-
ing possibility that induced changes in lipid membranes may
represent a common toxic motif. Continued research into the
mechanism of interaction between specific conformers capable of
seeding aggregation with cellular membranes is needed to fully
understand how amyloid propagates from cell to cell (Munch
and Bertolotti, 2012). How specific changes in cellular proper-
ties, such as membrane mechanics, influence the susceptibility
of specific cells to the prion-like propagation of these protein
aggregates remain unclear (Cecchi et al., 2007). Here, we high-
lighted some specific features of amyloid aggregation at model
surfaces and lipid membranes. While the studies reviewed here
are not exhaustive, we hope that collectively they offer a com-
pelling argument that such surface induced aggregation may play
a role in a variety of toxic mechanisms associated with these
diseases.
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